Theravance Biopharma (TBPH) Tops Q2 EPS by 119c, misses on revenue

Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of $0.98, $1.19 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $13.75 million versus the consensus estimate of $15.29 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight